McKesson and CD&R strike $5.8bn deal to buy infusion services provider
Drug distributor McKesson and private equity firm Clayton Dubilier & Rice agreed to acquire at-home infusion therapy provider Option Care Health in a transaction valued at $5.8 billion. Under the terms of the definitive agreement announced on Tuesday, the buyers will take Option Care private at a per-share price of $32.05. The acquisition joins a major healthcare distributor with a leading independent provider of home and alternate-site infusion services. The definitive agreement was signed by CD&R, McKesson Corporation, and Option Care Health, moving the target company from the Nasdaq exchange into private ownership.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ McKesson and Clayton Dubilier & Rice agreed to buy infusion therapy provider Option Care Health in a deal worth about $5.8 billion.
- ✓ The per-share offer price for Option Care Health is $32.05.
- ✓ CD&R, McKesson Corporation, and Option Care Health entered into a definitive agreement for the acquisition.
What changed
McKesson and Clayton Dubilier & Rice reached a definitive agreement to acquire Option Care Health for $5.8 billion.
Live updates
-
McKesson and CD&R Agree to Buy Option Care in $5.8B Deal
Drug distributor McKesson and private equity firm Clayton Dubilier & Rice agreed to acquire at-home infusion therapy provider Option Care Health in a transaction valued at $5.8 billion. Under the terms of the definitive agreement announced on Tuesday, the buyers will take Option Care private at a per-share price of $32.05. The acquisition joins a major healthcare distributor with a leading independent provider of home and alternate-site infusion services. The definitive agreement was signed by CD&R, McKesson Corporation, and Option Care Health, moving the target company from the Nasdaq exchange into private ownership.
Why it matters
Option Care Health operates as a major provider of home and alternate-site infusion services, catering to patients who require complex therapy outside of traditional hospital settings. Private equity firm Clayton Dubilier & Rice partners with drug distributor McKesson on the acquisition to take the publicly traded company private. Healthcare sector buyouts of this scale draw scrutiny regarding market consolidation and distribution channels for specialized pharmaceuticals.
What is confirmed
- McKesson and Clayton Dubilier & Rice agreed to buy infusion therapy provider Option Care Health in a deal worth about $5.8 billion.
- The per-share offer price for Option Care Health is $32.05.
- CD&R, McKesson Corporation, and Option Care Health entered into a definitive agreement for the acquisition.
What to watch next
- Regulatory approval timelines for the $5.8 billion acquisition
- Shareholder vote details regarding the take-private transaction
confidence 100%Sources used for this update (8)
- Financial Times — McKesson and CD&R strike $5.8bn deal to buy infusion services provider
- Reuters — McKesson, CD&R to take infusion therapy provider Option Care private in $5.8 billion deal
- Bloomberg.com — McKesson, CD&R to Buy Option Care in $5.8 Billion Deal
- Yahoo Finance — Option Care Health Agrees to $5.8 Billion Acquisition by CD&R and McKesson at $32.05 Per Share
- WSJ — CD&R, McKesson to Acquire At-Home Infusion Therapy Provider for $5.8 Billion
- finance.yahoo.com — McKesson, CD&R to buy infusion therapy provider Option Care ...
- www.mckesson.com — CD&R and McKesson Corporation Sign Agreement to Acquire ...
- www.cdr.com — CD&R and McKesson Corporation Sign Agreement to Acquire ...
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community